{"url_path":"/sec/vrdn/8-k/2026-06-03/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1590750/0001193125-26-254560-index.html","accession_number":"0001193125-26-254560","cik":"0001590750","ticker":"VRDN","issuer_name":"Viridian Therapeutics, Inc.\\DE","edgar_url":"https://www.sec.gov/Archives/edgar/data/1590750/0001193125-26-254560-index.html","primary_entity_key":"0001590750","primary_entity_name":"Viridian Therapeutics, Inc.\\DE"},"word_count":311,"has_tables":true,"body_markdown":"Item 5.07\n\nSubmission of Matters to a Vote of Security Holders.\n\nOn June 2, 2026, Viridian Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) at which holders of the Company’s common stock as of the close of business on April 7, 2026 (the “Record Date”) were entitled to vote. As of the close of business on the Record Date, 103,071,889 shares of the Company’s common stock were issued and outstanding.\n\nAt the Annual Meeting, each of the Company’s director nominees was elected and the other proposals voted on were approved. The final voting results are set forth below:\n\n1. Election of the two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders:\n\n \n\n \n  \nFor\n \n  \nWithheld\n \n  \nBroker Non-Votes\n \n\nTomas Kiselak\n\n  \n \n72,363,500\n \n  \n \n14,475,646\n \n  \n \n6,733,104\n \n\nJennifer K. Moses\n\n  \n \n86,378,842\n \n  \n \n460,304\n \n  \n \n6,733,104\n \n\n2. Ratification of the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026:\n\n \n\nFor\n\n \n\nAgainst\n\n \n\nAbstentions\n\n \n\nBroker Non-Votes\n\n92,866,008\n \n512,582\n \n193,660\n \n—\n\n3. Approval, on an advisory basis, of the compensation of the Company’s named executive officers:\n\n \n\nFor\n\n \n\nAgainst\n\n \n\nAbstentions\n\n \n\nBroker Non-Votes\n\n83,512,086\n \n3,113,724\n \n213,336\n \n6,733,104\n\n4. Approval, on an advisory basis, of the frequency of holding an advisory vote on the compensation of the Company’s named executive officers:\n\n \n\n1 Year\n\n \n\n2 Years\n\n \n\n3 Years\n\n \n\nAbstain\n\n86,084,347\n \n29,762\n \n517,682\n \n207,355\n\nAs a result of the foregoing vote, the Company’s Board of Directors has determined that the Company will conduct a non-binding advisory vote on the compensation of the Company’s named executive officers every year.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nViridian Therapeutics, Inc.\n\nDate: June 3, 2026\n \n\n \nBy:\n \n\n/s/ Stephen Mahoney\n\n \n\n \n\n \nStephen Mahoney\n\n \n\n \n\n \nPresident and Chief Executive Officer"}